Angiogenesis in the Treatment of Critical Limb Ischemia

Jason A. Chin*, Zankhana Raval, Melina R. Kibbe, Douglas W. Losordo

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter


This chapter reviews emerging evidence from the fields of gene and cell-based therapies for the management of patients with critical limb ischemia (CLI). Arteriogenesis, also called collateral growth, is the increase in the caliber of pre-existing collateral arterioles capable of compensating for the loss of function of occluded arteries. Vascular endothelial growth factor was one of the early growth factors to be investigated to induce angiogenesis in ischemic tissues. Hypoxia inducible factor-1 (HIF-1) is a recently investigated target for gene therapy in CLI. More than just an endothelial growth factor, it is a transcriptional activator and serves as a master regulator of oxygen homeostasis. A logical direction for future research may be to combine growth factor and cell-based therapy; intramuscular gene therapy could be administered in the ischemic tissue as pretreatment of the target tissue to augment homing of implanted stem cells.

Original languageEnglish (US)
Title of host publicationUrgent Interventional Therapies
Number of pages20
ISBN (Electronic)9781118504499
ISBN (Print)9780470672020
StatePublished - Nov 17 2014


  • Angiogenesis
  • Arteriogenesis
  • Critical limb ischemia (CLI)
  • Hypoxia inducible factor-1 (HIF-1)
  • Oxygen homeostasis
  • Stem cells
  • Vascular endothelial growth factor (VEGF)

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Angiogenesis in the Treatment of Critical Limb Ischemia'. Together they form a unique fingerprint.

Cite this